🔗 Share this article

Treasury head Reeves has revealed she is preparing "targeted action to address cost of living challenges" in the forthcoming Budget.

Speaking to media outlets, she emphasized that reducing price rises is a collective duty of both the government and the Bank of England.

The UK's price growth is projected to be the most elevated among the G7 industrialized countries this year and next.

Possible Energy Bill Measures

It is understood the government could intervene to reduce energy bills, for instance by slashing the present 5% rate of value-added tax charged on energy supplies.

An additional approach is to cut some of the government charges presently added to household expenses.

Budgetary Limitations and Expert Predictions

The administration will receive the next assessment from the official forecaster, the Office for Budget Responsibility, on the start of the week, which will clarify how much scope there is for such measures.

The view from the majority of experts is that the Chancellor will have to introduce higher taxes or expenditure reductions in order to fulfill her self-imposed debt limits.

Previously on the same day, calculations indicated there was a £22 billion shortfall for the chancellor to fill, which is at the more modest range of expectations.

"It is a joint task between the central bank and the government to continue tackling some of the causes of price increases," Reeves stated to the BBC in Washington, at the yearly gatherings of the IMF and global financial institution.

Revenue Pledges and International Concerns

While much of the attention has been on expected tax increases, the chancellor said the most recent data from the fiscal watchdog had not changed her pledge to manifesto promises not to raise tax levels on earnings tax, VAT or National Insurance.

She attributed an "uncertain world" with rising international and commercial tensions for the fiscal revenue measures, likely to be directed on those "most able to pay."

International Economic Disputes

Commenting on concerns about the UK's economic relations with the Asian nation she said: "Our security interests always take priority."

Last week's declaration by China to increase export controls on rare earths and other resources that are crucial for advanced tech manufacturing led US President Donald Trump to propose an further 100% tariff on goods from the Asian country, increasing the risk of an all-out trade war between the two global powers.

The US Treasury Secretary labeled China's decision "economic coercion" and "a global supply chain control attempt."

Questioned on considering the US offer to participate in its conflict with the Asian nation, the Chancellor said she was "very concerned" by China's measures and encouraged the Beijing authorities "not to put up barriers and restrict access."

She said the decision was "harmful for the world economy and generates further obstacles."

"In my view there are fields where we must challenge Chinese policies, but there are also significant prospects to export to Chinese markets, including banking sector and other areas of the economy. We've got to achieve that equilibrium right."

The chancellor also confirmed she was collaborating with international partners "on our own critical minerals approach, so that we are more independent."

Health Service Drug Pricing and Investment

The Chancellor also acknowledged that the cost the National Health Service pays for medicines could increase as a result of ongoing discussions with the Trump administration and its drugs companies, in return for reduced taxes and investment.

Some of the world's largest drug companies have said recently that they are either pausing or scrapping investments in the United Kingdom, with several blaming the modest returns they are obtaining.

Last month, the Science Minister said the price the health service spends on drugs would must rise to stop firms and pharmaceutical investment leaving the United Kingdom.

The Chancellor stated to the BBC: "We have seen as a result of the cost structure, that clinical trials, recent pharmaceuticals have not been available in the UK in the manner that they are in other EU nations."

"We want to ensure that patients getting care from the National Health Service are can receive the finest essential drugs in the globe. And so we are looking at all of that, and... looking to obtain additional capital into the UK."